{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:48:45Z","timestamp":1778658525940,"version":"3.51.4"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and objectives<\/jats:title>\n                  <jats:p>Botulinum toxin injection has been used for many years for various indications such as cervical dystonia, blepharospasm, oromandibular dystonia, hemifacial spasm in neurology. Botulinum toxin injections have been made in our clinic for about ten years. We want to report our experiences about botulinum toxin treatment in neurologic disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study, the data of the patients receiving BoNT injection between January 2018 and December 2019 was retrospectively analyzed. Age, gender, botulinum toxin indications, and mean dose, duration of efficacy, side effects noted for each injection were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 122 patients who received botulinum toxin injections between January 2018 and December 2019. Of the 122 patients identified, 28 had cervical dystonia, 61 had HFS, 21 had blepharospasm, 4 had generalized dystonia, 1 had hemidystonia following thalamic bleeding, 1 had tardive dystonia, 4 had migraine, 1 had bruxism and 1 had both migraine and bruxism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BoNT injection is a treatment that has been used for various indications in neurology for almost 40 years. Side effects are limited and temporary with appropriate injections. We also had a wide range of indication profiles and high numbers of patients to whom we administered the BoNT treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2478\/jtim-2021-0003","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:03:14Z","timestamp":1610362994000},"page":"52-56","source":"Crossref","is-referenced-by-count":4,"title":["Experiences on the administration of botulinum toxin in movement disorders"],"prefix":"10.2478","volume":"9","author":[{"given":"Buket","family":"Tu\u011fan Y\u0131ld\u0131z","sequence":"first","affiliation":[{"name":"Kahramanmara\u015f S\u00fct\u00e7\u00fc \u0130mam University , School of Medicine, Department of Neurology , Kahramanmara\u015f , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Tuncel Berkta\u015f","sequence":"additional","affiliation":[{"name":"Kahramanmara\u015f S\u00fct\u00e7\u00fc \u0130mam University , School of Medicine, Department of Neurology , Kahramanmara\u015f , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"2023042508101962685_j_jtim-2021-0003_ref_001","unstructured":"Matur Z, Parman Y. Botulinum toksininin n\u00f6rolojide kullan\u0131m alanlar\u0131. Klinik Geli\u015fim 2010; 23: 121\u20137."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_002","unstructured":"T\u00fcrker H, Onar M, Demir O, Tunal\u0131 G. Ondokuz May\u0131s \u00dcniversitesi N\u00f6roloji Klini\u011finde Botulinum Toksin Uygulamalar\u0131: Retrospektif Bir \u00c7al\u0131\u015fma. O. M. \u00dc. T\u0131p Derg 2007; 24: 6\u201314."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_003","unstructured":"Cardoso F, Jankovic J. Blepharospasm. Handbook of dystonia. Marcel Dekker 1995: 129\u201341."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_004","unstructured":"\u00c7akmur R. Botulinum Toxin Treatment of Blepharospasm and Hemifacial Spasm. Arch Neuropsychiatry 2010; 47: 6\u201310."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_005","doi-asserted-by":"crossref","unstructured":"Chaudhry N, Srivastava A, Joshi L. Hemifacial spasm: The past, present and future. J Neurol Sci 2015; 356: 27\u201331.","DOI":"10.1016\/j.jns.2015.06.032"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_006","unstructured":"Parman Y, Matur Z. Botulinum toksini ile ekstremite uygulamalar\u0131. N\u00f6ropsikiyatri Ar\u015fivi 2006; 43: 20\u201323."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_007","doi-asserted-by":"crossref","unstructured":"Misra VP, Danchenko N, Maisonobe P, Lundkvist J, Hunger M. Economic evaluation of AbobotulinumtoxinA vs. OnabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord 2020; 7: 3\u201310.","DOI":"10.1186\/s40734-020-0083-0"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_008","doi-asserted-by":"crossref","unstructured":"Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6: 119\u201326.","DOI":"10.1002\/mds.870060206"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_009","doi-asserted-by":"crossref","unstructured":"Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125\u201333.","DOI":"10.1016\/j.pain.2003.10.008"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_010","doi-asserted-by":"crossref","unstructured":"Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007; 120: 2864\u201374.","DOI":"10.1242\/jcs.012211"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_011","doi-asserted-by":"crossref","unstructured":"Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009; 141: 60\u20139.","DOI":"10.1016\/j.pain.2008.10.005"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_012","doi-asserted-by":"crossref","unstructured":"Aydinlar EI, Dikmen PY, Sa\u011fduyu A. Botulinum Toxin in Migraine Treatment. Arch Neuropsychiatry 2013; 50: 36\u201340.","DOI":"10.4274\/npa.y7198"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_013","unstructured":"Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734\u201370."},{"key":"2023042508101962685_j_jtim-2021-0003_ref_014","doi-asserted-by":"crossref","unstructured":"Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm (Vienna) 2010; 117: 759\u201363.","DOI":"10.1007\/s00702-010-0409-4"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_015","doi-asserted-by":"crossref","unstructured":"Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 2009; 16: 392\u20138.","DOI":"10.1111\/j.1468-1331.2008.02507.x"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_016","doi-asserted-by":"crossref","unstructured":"Lee JM, Baek JS, Choi HS, Kim SJ, Jang JW. Clinical Features of Benign Essential Blepharospasm in Korean Patients. Korean J Ophthalmol 2018; 32: 339\u201343.","DOI":"10.3341\/kjo.2018.0038"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_017","doi-asserted-by":"crossref","unstructured":"Aquino CC, Fel\u00edcio AC, Castro PC, Oliveira RA, Silva SM, Borges V, et al. Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience. Arq Neuropsiquiatr 2012; 70: 662\u20136.","DOI":"10.1590\/S0004-282X2012000900003"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_018","doi-asserted-by":"crossref","unstructured":"LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet 2016; 2: e69.","DOI":"10.1212\/NXG.0000000000000069"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_019","doi-asserted-by":"crossref","unstructured":"Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 2015; 349: 84\u201393.","DOI":"10.1016\/j.jns.2014.12.030"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_020","doi-asserted-by":"crossref","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. PREEMPT 1 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793\u2013803.","DOI":"10.1177\/0333102410364676"},{"key":"2023042508101962685_j_jtim-2021-0003_ref_021","doi-asserted-by":"crossref","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804\u201314.","DOI":"10.1177\/0333102410364677"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jtim\/ahead-of-print\/article-10.2478-jtim-2021-0003\/article-10.2478-jtim-2021-0003.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2021-0003\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2021-0003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:20:43Z","timestamp":1682410843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2021-0003\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,3,31]]}},"alternative-id":["10.2478\/jtim-2021-0003"],"URL":"https:\/\/doi.org\/10.2478\/jtim-2021-0003","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}